Shire (SHP) Given Buy Rating at Shore Capital
Shire (LON:SHP)‘s stock had its “buy” rating reaffirmed by equities researchers at Shore Capital in a research note issued to investors on Monday.
SHP has been the subject of several other research reports. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 5,300 ($71.87) price target on shares of Shire in a report on Monday, October 30th. Liberum Capital lowered their price target on Shire from GBX 4,400 ($59.67) to GBX 4,200 ($56.96) and set a “hold” rating for the company in a report on Tuesday, October 24th. Barclays reissued an “equal weight” rating and issued a GBX 4,000 ($54.24) price target on shares of Shire in a report on Monday, October 30th. Deutsche Bank reissued a “buy” rating on shares of Shire in a report on Monday, December 11th. Finally, Kepler Capital Markets reaffirmed a “buy” rating and set a GBX 4,600 ($62.38) target price on shares of Shire in a report on Friday, November 17th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Shire has an average rating of “Buy” and an average price target of GBX 5,152.94 ($69.88).
Shares of Shire (LON SHP) traded down GBX 45 ($0.61) during midday trading on Monday, reaching GBX 3,536 ($47.95). The company’s stock had a trading volume of 3,352,065 shares, compared to its average volume of 2,280,000. The firm has a market capitalization of $31,720.00 and a P/E ratio of 2,741.09. Shire has a fifty-two week low of GBX 3,435.50 ($46.59) and a fifty-two week high of GBX 5,067 ($68.71).
COPYRIGHT VIOLATION NOTICE: “Shire (SHP) Given Buy Rating at Shore Capital” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/15/shire-shp-given-buy-rating-at-shore-capital-2.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.